 Bradley Dixon
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atypical Hemolytic Uremic Syndrome | 8 | 2024 | 22 | 2.230 |
Why?
| | Thrombotic Microangiopathies | 6 | 2020 | 20 | 1.100 |
Why?
| | Kidney Diseases | 5 | 2022 | 406 | 1.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2024 | 852 | 0.730 |
Why?
| | Tuberous Sclerosis | 4 | 2017 | 55 | 0.640 |
Why?
| | TRPM Cation Channels | 2 | 2019 | 75 | 0.640 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2025 | 14 | 0.630 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2019 | 668 | 0.600 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2019 | 14 | 0.600 |
Why?
| | Nephrotic Syndrome | 3 | 2025 | 39 | 0.600 |
Why?
| | Kidney | 9 | 2024 | 1482 | 0.560 |
Why?
| | DNA Damage | 2 | 2011 | 427 | 0.530 |
Why?
| | Osmoregulation | 1 | 2017 | 4 | 0.530 |
Why?
| | Kidney Tubules, Collecting | 1 | 2017 | 27 | 0.520 |
Why?
| | Osmotic Pressure | 1 | 2017 | 34 | 0.520 |
Why?
| | Autoimmunity | 1 | 2020 | 908 | 0.440 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 819 | 0.410 |
Why?
| | Autoantibodies | 2 | 2020 | 1470 | 0.400 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 623 | 0.400 |
Why?
| | Lupus Nephritis | 2 | 2022 | 67 | 0.360 |
Why?
| | Complement System Proteins | 4 | 2022 | 332 | 0.360 |
Why?
| | Epithelial Cells | 2 | 2019 | 1110 | 0.350 |
Why?
| | Urothelium | 1 | 2011 | 37 | 0.340 |
Why?
| | Hypertension | 3 | 2025 | 1252 | 0.340 |
Why?
| | Cell Line | 3 | 2019 | 2885 | 0.340 |
Why?
| | Proteinuria | 3 | 2025 | 99 | 0.330 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 854 | 0.320 |
Why?
| | Kidney Transplantation | 4 | 2024 | 675 | 0.310 |
Why?
| | Complement Inactivating Agents | 3 | 2023 | 66 | 0.300 |
Why?
| | Osmolar Concentration | 1 | 2009 | 167 | 0.300 |
Why?
| | RecQ Helicases | 1 | 2008 | 9 | 0.290 |
Why?
| | Angiomyolipoma | 3 | 2014 | 23 | 0.290 |
Why?
| | Cell Cycle | 1 | 2011 | 597 | 0.270 |
Why?
| | Complement C3 | 2 | 2025 | 203 | 0.270 |
Why?
| | Purines | 1 | 2008 | 179 | 0.260 |
Why?
| | Urinary Bladder | 1 | 2009 | 194 | 0.260 |
Why?
| | Escherichia coli Proteins | 1 | 2008 | 201 | 0.250 |
Why?
| | Humans | 40 | 2025 | 141197 | 0.240 |
Why?
| | Nephrology | 2 | 2024 | 61 | 0.240 |
Why?
| | Prenatal Injuries | 1 | 2005 | 1 | 0.230 |
Why?
| | Hypertension, Renal | 1 | 2005 | 16 | 0.230 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 17 | 0.230 |
Why?
| | Nephrocalcinosis | 1 | 2024 | 13 | 0.220 |
Why?
| | Child | 20 | 2025 | 22310 | 0.220 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.220 |
Why?
| | Hematoma | 1 | 2005 | 54 | 0.220 |
Why?
| | Pyrimidines | 1 | 2008 | 477 | 0.220 |
Why?
| | Kidney Diseases, Cystic | 2 | 2017 | 25 | 0.220 |
Why?
| | Rituximab | 1 | 2025 | 204 | 0.210 |
Why?
| | Polycystic Kidney Diseases | 1 | 2005 | 73 | 0.210 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2024 | 45 | 0.210 |
Why?
| | Peptides, Cyclic | 1 | 2025 | 266 | 0.210 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2017 | 31 | 0.210 |
Why?
| | Kidney Neoplasms | 3 | 2014 | 405 | 0.210 |
Why?
| | Disease Management | 2 | 2020 | 633 | 0.210 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 750 | 0.200 |
Why?
| | Nephritis | 1 | 2023 | 24 | 0.200 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2022 | 7 | 0.190 |
Why?
| | Femur Head Necrosis | 1 | 2022 | 14 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 308 | 0.190 |
Why?
| | Terminology as Topic | 1 | 2024 | 244 | 0.190 |
Why?
| | Pharmacists | 1 | 2025 | 263 | 0.190 |
Why?
| | Arthritis, Juvenile | 1 | 2022 | 54 | 0.190 |
Why?
| | Complement Factor B | 1 | 2023 | 110 | 0.190 |
Why?
| | Self-Management | 1 | 2025 | 205 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 307 | 0.180 |
Why?
| | DNA | 1 | 2008 | 1444 | 0.180 |
Why?
| | Rheumatology | 1 | 2022 | 110 | 0.170 |
Why?
| | Antihypertensive Agents | 1 | 2025 | 508 | 0.170 |
Why?
| | Recurrence | 1 | 2024 | 1110 | 0.170 |
Why?
| | Glomerulonephritis | 1 | 2019 | 47 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 234 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 325 | 0.150 |
Why?
| | Cilia | 2 | 2019 | 172 | 0.150 |
Why?
| | Plasma Exchange | 1 | 2019 | 18 | 0.150 |
Why?
| | Hirschsprung Disease | 1 | 2020 | 89 | 0.150 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2181 | 0.150 |
Why?
| | Electronic Health Records | 3 | 2023 | 1122 | 0.150 |
Why?
| | Renal Dialysis | 2 | 2022 | 457 | 0.150 |
Why?
| | Critical Illness | 2 | 2023 | 837 | 0.150 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 81 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2020 | 352 | 0.140 |
Why?
| | Plasmapheresis | 1 | 2018 | 24 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 93 | 0.140 |
Why?
| | Escherichia coli Infections | 1 | 2019 | 117 | 0.140 |
Why?
| | Fluid Therapy | 1 | 2019 | 138 | 0.140 |
Why?
| | Sirolimus | 2 | 2017 | 277 | 0.140 |
Why?
| | Blood Component Transfusion | 1 | 2018 | 95 | 0.130 |
Why?
| | Risk Factors | 4 | 2024 | 10438 | 0.130 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2017 | 3 | 0.130 |
Why?
| | GABA Plasma Membrane Transport Proteins | 1 | 2017 | 7 | 0.130 |
Why?
| | Transfection | 2 | 2017 | 943 | 0.130 |
Why?
| | Saline Solution, Hypertonic | 1 | 2017 | 41 | 0.130 |
Why?
| | Streptococcal Infections | 1 | 2019 | 151 | 0.130 |
Why?
| | TRPV Cation Channels | 1 | 2017 | 42 | 0.130 |
Why?
| | Erythrocyte Transfusion | 1 | 2019 | 203 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 220 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 464 | 0.120 |
Why?
| | Adolescent | 11 | 2025 | 22007 | 0.120 |
Why?
| | Gene Editing | 1 | 2017 | 86 | 0.120 |
Why?
| | Patient Selection | 1 | 2019 | 688 | 0.120 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 150 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 197 | 0.120 |
Why?
| | Child, Preschool | 8 | 2025 | 11457 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1498 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 184 | 0.110 |
Why?
| | Treatment Outcome | 7 | 2025 | 11120 | 0.110 |
Why?
| | Pericytes | 1 | 2014 | 35 | 0.110 |
Why?
| | Male | 15 | 2025 | 69789 | 0.100 |
Why?
| | Complement Membrane Attack Complex | 1 | 2013 | 38 | 0.100 |
Why?
| | Female | 16 | 2025 | 75522 | 0.100 |
Why?
| | Caregivers | 1 | 2022 | 932 | 0.100 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2014 | 101 | 0.100 |
Why?
| | Infant | 6 | 2025 | 9818 | 0.100 |
Why?
| | Complement Factor D | 2 | 2022 | 28 | 0.100 |
Why?
| | Transplantation, Autologous | 2 | 2013 | 280 | 0.090 |
Why?
| | Complement Pathway, Alternative | 1 | 2013 | 123 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 159 | 0.090 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 118 | 0.090 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2011 | 18 | 0.090 |
Why?
| | Nephrolithiasis | 1 | 2010 | 10 | 0.090 |
Why?
| | Creatinine | 2 | 2025 | 489 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4073 | 0.080 |
Why?
| | Mice | 3 | 2019 | 18055 | 0.070 |
Why?
| | Young Adult | 5 | 2025 | 13673 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2009 | 47 | 0.070 |
Why?
| | Complement Activation | 2 | 2022 | 414 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3470 | 0.070 |
Why?
| | Organ Specificity | 1 | 2009 | 312 | 0.070 |
Why?
| | Kanamycin Resistance | 1 | 2008 | 2 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2025 | 16273 | 0.070 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2008 | 28 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 7739 | 0.070 |
Why?
| | Mutation | 2 | 2010 | 4013 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 951 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2794 | 0.070 |
Why?
| | Stomach Neoplasms | 1 | 2009 | 118 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2011 | 256 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 169 | 0.070 |
Why?
| | Blood Pressure | 2 | 2025 | 1748 | 0.070 |
Why?
| | DNA Repair | 1 | 2009 | 234 | 0.070 |
Why?
| | Stress, Mechanical | 1 | 2009 | 489 | 0.070 |
Why?
| | Plasmids | 1 | 2008 | 365 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 246 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2008 | 339 | 0.060 |
Why?
| | DNA Replication | 1 | 2008 | 240 | 0.060 |
Why?
| | Biomarkers | 3 | 2023 | 4175 | 0.060 |
Why?
| | Signal Transduction | 2 | 2017 | 5144 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5887 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1234 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2025 | 35 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2793 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2025 | 106 | 0.060 |
Why?
| | Kidney Glomerulus | 1 | 2025 | 121 | 0.060 |
Why?
| | Nucleic Acid Conformation | 1 | 2008 | 725 | 0.060 |
Why?
| | Repressor Proteins | 1 | 2008 | 425 | 0.060 |
Why?
| | Adult | 6 | 2025 | 39181 | 0.060 |
Why?
| | Apoptosis | 2 | 2012 | 2574 | 0.050 |
Why?
| | Animals | 3 | 2019 | 37663 | 0.050 |
Why?
| | Escherichia coli | 1 | 2008 | 838 | 0.050 |
Why?
| | Remission Induction | 1 | 2024 | 309 | 0.050 |
Why?
| | Algorithms | 2 | 2021 | 1763 | 0.050 |
Why?
| | Middle Aged | 4 | 2025 | 34438 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 193 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2023 | 214 | 0.050 |
Why?
| | Graft Survival | 1 | 2024 | 499 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 704 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1983 | 0.040 |
Why?
| | Complement C5 | 1 | 2020 | 80 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 844 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 541 | 0.040 |
Why?
| | Forms and Records Control | 1 | 2019 | 21 | 0.040 |
Why?
| | Information Services | 1 | 2019 | 49 | 0.040 |
Why?
| | Pregnenolone | 1 | 2019 | 3 | 0.040 |
Why?
| | Gelatinases | 1 | 2019 | 7 | 0.040 |
Why?
| | Fibrinogen | 1 | 2020 | 180 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3709 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 123 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 288 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 324 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 65 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1556 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 138 | 0.040 |
Why?
| | Flavonoids | 1 | 2019 | 85 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2019 | 117 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2892 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 147 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 586 | 0.030 |
Why?
| | United States | 2 | 2025 | 15220 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 250 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2902 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1081 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 531 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2015 | 116 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 868 | 0.030 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 23 | 0.030 |
Why?
| | Valsartan | 1 | 2014 | 30 | 0.030 |
Why?
| | Tetrazoles | 1 | 2014 | 44 | 0.030 |
Why?
| | Complement Hemolytic Activity Assay | 1 | 2013 | 2 | 0.030 |
Why?
| | Valine | 1 | 2014 | 77 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2013 | 23 | 0.030 |
Why?
| | Angiotensin II | 1 | 2014 | 99 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 77 | 0.030 |
Why?
| | Veterans | 1 | 2025 | 1514 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3166 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 198 | 0.020 |
Why?
| | Leupeptins | 1 | 2012 | 12 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 413 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 43 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2012 | 33 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2012 | 29 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1093 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2013 | 217 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5636 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 100 | 0.020 |
Why?
| | Everolimus | 1 | 2012 | 110 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5799 | 0.020 |
Why?
| | Pregnancy | 1 | 2005 | 7070 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 771 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 388 | 0.020 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 129 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 250 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2999 | 0.020 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 169 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1319 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3004 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 61 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 423 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 144 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6275 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1859 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1187 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1768 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 2504 | 0.020 |
Why?
| | Proteins | 1 | 2012 | 1010 | 0.020 |
Why?
| | Aged | 1 | 2025 | 24576 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2166 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6956 | 0.010 |
Why?
|
|
Dixon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|